文献速递浆细胞疾病

识别MGUS和冒烟型骨髓瘤的疾病进展:生物标志物、症状监测与影像学

Recognising disease progression in MGUS and smouldering myeloma: Biomarkers, symptom monitoring and imaging.
PubMed 文献 · Br J Haematol · 2026-05-20

TEAMM试验从93家英国医院招募977例新诊断骨髓瘤患者,分析其中133例(14%)既往有MGUS或SMM前驱疾病者。结果显示,前驱病患者在进展前症状持续时间是无前驱期患者的5倍;仅29%报告新发骨髓瘤相关症状,但70%在进展前副蛋白显著升高;25%发生骨折,仅40%报告背痛合并椎体骨折。

要点

  • 前驱病患者进展前症状持续时间长,但新发症状报告率低(29%)。
  • 副蛋白显著升高是进展的常见指标(70%),风险评分在进展前升高。
  • 骨折发生率高(25%),但生物标志物特异性不足,仅40%报告背痛合并椎体骨折。

核心结论

  • 使用患者报告症状和单克隆免疫球蛋白监测来及时识别前驱疾病进展仍面临持续挑战。

研究设计与样本

  • TEAMM试验事后分析,从93家英国医院招募977例新诊断骨髓瘤患者,分析其中133例(14%)既往有MGUS或SMM前驱疾病者。

主要发现

  • 前驱病患者在进展为活动性骨髓瘤前症状持续时间为无前驱期患者的5倍。
  • 仅29%患者在首次血液科预约后报告新发骨髓瘤相关症状,但70%在进展前副蛋白水平显著升高。
  • MGUS和SMM风险评分在进展前均升高。
  • 25%患者发生骨折,尽管正在监测前驱疾病。
  • 生物标志物缺乏特异性,仅40%患者报告背痛合并椎体骨折。

临床怎么用

  • 临床中应结合副蛋白监测、风险评分和影像学综合评估前驱疾病进展,不能仅依赖患者报告症状。

局限性

  • 骨折难以预测,生物标志物缺乏特异性,且仅40%患者报告背痛合并椎体骨折。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Tackling Early Morbidity and Mortality in Myeloma trial (TEAMM) trial recruited 977 newly diagnosed myeloma patients from 93 UK hospitals to assess the advantages and disadvantages of prophylactic antibiotics for the first 12 weeks. This paper analyses the 133 (14%) patients who had previously known precursor disease including monoclonal gammopathy of undetermined significance (MGUS) and smouldering myeloma (SMM), reporting the relative importance of blood-based biomarkers, imaging findings and symptoms in their management. Prior to progression with active myeloma, patients with precursor conditions had symptoms for five times longer than patients with no diagnosed precursor phase. Although only 29% of patients reported new myeloma-related symptoms developing after their first haematology appointment, 70% had a significant rise in paraprotein levels prior to progression. Likewise, risk scores for both MGUS and SMM increased prior to progression. Fractures occurred in 25% of patients despite being monitored for precursor disease. These fractures were difficult to predict as biomarkers lacked specificity and only 40% of patients reported back pain in combination with vertebral fractures. This study highlights the ongoing challenge of promptly recognising disease progression when using patient-reported symptoms and monoclonal immunoglobulin monitoring.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Haslam A, Iqbal G, Drayson M, et al. Recognising disease progression in MGUS and smouldering myeloma: Biomarkers, symptom monitoring and imaging. Br J Haematol. 2026. PMID: 42162568. doi:10.1111/bjh.70492

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。